Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.44), $0.22 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $75 million versus the consensus estimate of $74 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.